AstraZeneca at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
AstraZeneca takes part in 4 sessions at TIDES Europe 2026 in Amsterdam. Its sessions span oligonucleotide and peptide manufacturing, from rethinking the green credentials of oligonucleotide production to fragment-based peptide synthesis routes that enable a move to liquid phase. It also addresses diastereomeric control in phosphorothioate siRNAs and peptide-targeted delivery of oligonucleotide therapeutics.
| Organization | TIDES Europe 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing medicines across modalities, including oligonucleotide and peptide therapeutics. | Talk Thu Nov 5 15:00–15:30 Maintaining Diastereomeric Control in Phosphorothioate siRNAs: Integrated Analytical and Manufacturing Approaches for Reliable Clinical Development Why purifying siRNA can quietly shift the mix of mirror-image sulfur linkages between batches, and how to keep that mix steady. Talk Thu Nov 5 09:05–09:35 Peptide-Targeted Delivery of Oligonucleotide Therapeutics Early, pre-clinical work on a short peptide that steers gene-silencing drugs into the tissue where they are meant to act. Talk Thu Nov 5 09:05–09:35 Rethinking Green Credentials for Oligo Manufacturing Why simple waste-per-kilogram scores misjudge how green oligonucleotide production is, and what real improvement would involve. Talk Thu Nov 5 08:35–09:05 Systematic Route Design for Fragment-Based Peptide Synthesis: Enabling Liquid-Phase Transition A way to choose where to split a long peptide into fragments so it can be built in solution with better yield. |
Instantly find 20 buyers from AstraZeneca
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Informa Connect or TIDES Europe. Submit a correction